ABT-126 is an α7nAChR agonist in clinical trials for AD treatment; oral ABT-126 dose-dependently decreased dyskinesias by about 60% in MPTP-induced PD squirrel monkeys on levodopa/carbidopa therapy [74]. Here, CHRNA7 is linked to drug-induced dyskinesia.